LEUKOCARE and Boehringer Ingelheim enter into a license agreement in the field of veterinary diagnostics
© LEUKOCARE AG
LEUKOCARE grants a license to Laboratorios Liomont
Biotechnology company LEUKOCARE AG, Germany, and Laboratorios Liomont S.A., Mexico, have entered into a license agreement in the field of biosimilar development. Under the terms of this agreement, Liomont will have access to LEUKOCARE´s SPS® technology platform and know-how to develop a novel formulation for one of Liomont’s pharmaceutical products.
Biotechnology company LEUKOCARE has gained another important partner for its Stabilizing and Protecting Solutions (SPS®) technologies. As the company from Martinsried near Munich announced, LEUKOCARE has signed a license agreement with Boehringer Ingelheim. Based on this agreement, the animal health division of pharmaceutical company Boehringer Ingelheim will use LEUKOCARE’s SPS® formulation technologies to deploy and stabilize biological reagents in a new veterinary diagnostics product. License and payment terms have not been disclosed by the partners.
Michael Scholl, CEO, LEUKOCARE
© LEUKOCARE AG
Michael Scholl, CEO of LEUKOCARE, commented: “After having worked with Boehringer Ingelheim for a long time and being closely involved in their development activities, we are very pleased to be able to support our partner with our SPS® technologies in a specific application. This demonstrates once again the high quality of our SPS® formulation technology platform as well as our development expertise.